 |
|
|
| |
Safety and Efficacy at 4 Years in Post-Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide [vs TDF] for HBV Prophylaxis
|
| |
| |
AASLD 2021 Nov 12-15
Edward J. Gane,1 Bibin George,1 Dominic Ray-Chaudhuri,1 Thomas Mules,1 Curtis D. Holt,2 Hongyuan Wang,2 Vithika Suri,2 Anuj Gaggar,2 Anu 0. Osinusi,2 John F. Flaherty2
'New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland. New Zealand; 2Gilead Sciences, Inc. Foster City, CA
|
| |
|
|
|
|
|
